Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B

References

• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26(S6):1–158. 3rd ed. doi: 10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Castaman G, Matino D. Hemophilia a and B: molecular and clinical similarities and differences. Haematologica. 2019;104(9):1702–1709. doi: 10.3324/haematol.2019.221093
   PubMed Web of Science ®Google Scholar
• Bladen M, Main E, Hubert N, et al. Factors affecting the haemophilia joint health score in children with severe haemophilia. Haemophilia. 2013;19(4):626–631. doi: 10.1111/hae.12108
   PubMed Web of Science ®Google Scholar
• Van Vulpen, LFD,Holstein, KMartinoli, C, et al. Joint disease in haemophilia: pathophysiology, pain and imaging. Haemophilia. 2018;24(6):44–49. Suppl . doi: 10.1111/hae.13449
   PubMedGoogle Scholar
• Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia. 2014;20(4):459–463. doi: 10.1111/hae.12375
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544. doi: 10.1056/NEJMoa067659
   PubMed Web of Science ®Google Scholar
• Van Vulpen, LFD ,Van Meegeren, MER Roosendaal, G et al. Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in vivo study. Osteoarthritis Cartilage. 2015;23(1):63–69. doi: 10.1016/j.joca.2014.09.008
   PubMed Web of Science ®Google Scholar
• Hart DP, Matino D, Astermark J, et al. International consensus recommendations on the management of people with haemophilia B. Ther Adv Hematol. 2022;13:204062072210852. doi: 10.1177/20406207221085202
   Web of Science ®Google Scholar
• Burke T, Shaikh A, Ali TM, et al. Association of factor expression levels with annual bleeding rate in people with haemophilia B. Haemophilia. 2023;29(1):115–122. doi: 10.1111/hae.14675
   PubMedGoogle Scholar
• Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence. 2017;11:1677–1686. doi: 10.2147/PPA.S139851
   PubMed Web of Science ®Google Scholar
• Shapiro A, Potts J, Li S, et al. Association of bleeding tendency with time under target FIX activity levels in severe hemophilia B patients treated with recombinant factor IX Fc fusion protein. Blood. 2013;122(21):2349–2349. doi: 10.1182/blood.V122.21.2349.2349
   Web of Science ®Google Scholar
• Schrijvers LH, Beijlevelt-van der Zande M, Peters M, et al. Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. Br J Haematol. 2016;174(3):454–460. doi: 10.1111/bjh.14072
   PubMed Web of Science ®Google Scholar
• Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost. 2021;19(9):2112–2121. doi: 10.1111/jth.15444
   PubMed Web of Science ®Google Scholar
• duTreil S. Physical and psychosocial challenges in adult hemophilia patients with inhibitors. J Blood Med. 2014;5:115–122. doi: 10.2147/JBM.S63265
   PubMedGoogle Scholar
• DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol. 2007;138(3):305–315. doi: 10.1111/j.1365-2141.2007.06657.x
   PubMed Web of Science ®Google Scholar
• Curtis R, Baker J, Riske B, et al. Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status. Am J Hematol. 2015;90(2):S11–S16. Suppl. doi: 10.1002/ajh.24218
   PubMedGoogle Scholar
• Palareti L, Poti S, Cassis F, et al. Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: results from the HERO qualitative study. Int J Qual Stud Health Well-Being. 2015;10(1):28915. doi: 10.3402/qhw.v10.28915
   PubMedGoogle Scholar
• Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. doi: 10.1177/2040620718791933
   PubMed Web of Science ®Google Scholar
• Batty P, Lillicrap D. Hemophilia gene therapy: approaching the first licensed product. Hemasphere. 2021;5(3):e540. doi: 10.1097/HS9.0000000000000540
   PubMed Web of Science ®Google Scholar
• Perrin G, Herzog R, Markusic D. Update on clinical gene therapy for hemophilia. Blood. 2019;113(5):407–414. doi: 10.1182/blood-2018-07-820720
   Google Scholar
• Arruda VR, Doshi BS, Arruda VR. Gene therapy for hemophilia: facts and quandaries in the 21st century. Mediterr J Hematol Infect Dis. 2020;12(1):e2020069. doi: 10.4084/mjhid.2020.069
   PubMedGoogle Scholar
• Escobar M, Santagostino E, Mancuso ME, et al. Switching patients in the age of long-acting recombinant products? Expert Rev Hematol. 2019;12(sup1):1–13. doi: 10.1080/17474086.2018.1564032
   PubMed Web of Science ®Google Scholar
• Mancuso ME, Lubetsky A, Pan-Petesch B, et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost. 2020;18(5):1065–1074. doi: 10.1111/jth.14778
   PubMed Web of Science ®Google Scholar
• Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia a (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295–e305. doi: 10.1016/S2352-3026(19)30054-7
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia a with inhibitors. N Engl J Med. 2017;377(9):809–818. doi: 10.1056/NEJMoa1703068
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Kuliczkowski K, Karim FA, et al. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia a. Blood. 2016;128(5):630–637. doi: 10.1182/blood-2016-01-687434
   PubMed Web of Science ®Google Scholar
• Stasyshyn O, Djambas Khayat C, Iosava G, et al. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial. J Thromb Haemost. 2017;15(4):636–644. doi: 10.1111/jth.13647
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia a. Blood. 2014;123(3):317–325. doi: 10.1182/blood-2013-10-529974
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Shapiro AD, Liesner RJ, et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008;6(8):1319–1326. doi: 10.1111/j.1538-7836.2008.03032.x
   PubMed Web of Science ®Google Scholar
• Lissitchkov T, Rusen L, Georgiev P, et al. PK-guided personalized prophylaxis with Nuwiq((R)) (human-cl rhFVIII) in adults with severe haemophilia a. Haemophilia. 2017;23(5):697–704. doi: 10.1111/hae.13251
   PubMed Web of Science ®Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia a. Blood. 2015;126(9):1078–1085. doi: 10.1182/blood-2015-03-630897
   PubMed Web of Science ®Google Scholar
• BioMarin. ROCTAVIAN - Summary of product characteristics [Accessed Jun 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/roctavian-epar-product-information_en.pdf
   Google Scholar
• BioMarin. ROCTAVIAN - Prescribing Information [Accessed Oct 2023]. Available from: https://www.fda.gov/media/169937/download?attachment
   Google Scholar
• Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761–1769. doi: 10.1182/blood-2015-09-669234
   PubMed Web of Science ®Google Scholar
• Kenet G, Chambost H, Male C, et al. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. Thromb Haemost. 2016;116(4):659–668. doi: 10.1160/TH16-03-0179
   PubMed Web of Science ®Google Scholar
• Kavakli K, Smith L, Kuliczkowski K, et al. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia. 2016;22(3):381–388. doi: 10.1111/hae.12878
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313–2323. doi: 10.1056/NEJMoa1305074
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia Online Registry of Clotting Factor Concentrates 2023 [Apr 2023]. Available from: https://wfh.org/article/wfh-online-registry-of-clotting-factor-concentrates/
   Google Scholar
• Pfizer. Prescribing information - BeneFIX [Accessed Feb 2023]. Available from: https://www.fda.gov/media/73556/download
   Google Scholar
• Pfizer. BeneFIX - Summary of product characteristics [Accessed Feb 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/benefix-epar-product-information_en.pdf
   Google Scholar
• Takeda. Prescribing information - RIXUBIS [Accessed Feb 2023]. Available from: https://www.fda.gov/media/86123/download
   Google Scholar
• Takeda. RIXUBIS - Summary of product characteristics [Accessed Feb 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/rixubis-epar-product-information_en.pdf
   Google Scholar
• CSL Behring. IDELVION - Summary of product characteristics [Accessed Feb 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf
   Google Scholar
• CSL Behring. Prescribing information - IDELVION [Accessed Feb 2023]. Available from: https://www.fda.gov/media/96526/download
   Google Scholar
• Sobi. Prescribing Information - ALPROLIX [Accessed Feb 2023]. Available from: https://www.fda.gov/media/88119/download
   Google Scholar
• Sobi. ALPROLIX - Summary of product characteristics [Accessed Feb 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf
   Google Scholar
• Novo Nordisk. REFIXIA - Summary of product characteristics [Accessed Feb 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/refixia-epar-product-information_en.pdf
   Google Scholar
• Novo Nordisk. Prescribing information - REBINYN [Accessed Feb 2023]. Available from: https://www.fda.gov/media/105491/download
   Google Scholar
• CSL Behring. Prescribing information - HEMGENIX [Accessed Jan 2023]. Available from: https://www.fda.gov/media/163467/download
   Google Scholar
• CSL Behring. HEMGENIX - Summary of product characteristics 2023 [Mar 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/hemgenix-epar-product-information_en.pdf
   Google Scholar
• George LA, Sullivan SK, Rasko JEJ, et al. Efficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector fidanacogene elaparvovec and followed for at least 1 year. Blood. 2019;134(Supplement_1):3347–3347. doi: 10.1182/blood-2019-124091
   Google Scholar
• ClinicalTrials.gov; NCT03861273 [February 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT03861273
   Google Scholar
• Pasi KJ, Lissitchkov T, Mamonov V, et al. Targeting of antithrombin in hemophilia a or B with investigational siRNA therapeutic fitusiran-results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19(6):1436–1446. doi: 10.1111/jth.15270
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov; NCT03754790[Accessed Jun 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT03754790
   Google Scholar
• Shapiro A, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia a and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019;134(22):1973–1982. doi: 10.1182/blood.2019001542
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov; NCT04083781 [Accessed Jun 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT04083781
   Google Scholar
• Mahlangu J, Luis Lamas J, Cristobal Morales J, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results. Br J Haematol. 2023;200(2):240–248. doi: 10.1111/bjh.18495
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov; NCT03938792 [Accessed Jun 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT03938792
   Google Scholar
• Baglin T, Koch A, Mocanu I, et al. Serpinpc in persons with severe hemophilia (PwH): updated results from a multi-center, multi-part, first-in-human study. Blood. 2022;140(Supplement 1):460–461. doi: 10.1182/blood-2022-159631
   Google Scholar
• ClinicalTrials.gov; NCT05789524 [Accessed Jun 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT05789524
   Google Scholar
• Medicines and Healthcare products regulatory Agency. Orphan registered medicinal products: HEMGENIX 2023 [Mar 2023]. Available from: https://www.gov.uk/government/publications/orphan-registered-medicinal-products/orphan-register#hemgenix-1-x-1013-genome-copiesml-concentrate-for-solution-for-infusion
   Google Scholar
• George LA, Monahan PE, Eyster ME, et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia a. N Engl J Med. 2021;385(21):1961–1973. doi: 10.1056/NEJMoa2104205
   PubMed Web of Science ®Google Scholar
• Pfizer. Pfizer and sangamo therapeutics announce Phase 3 trial of investigational gene therapy for hemophilia a has re-opened recruitment 2022. Available from: https://www.pfizer.com/news/announcements/pfizer-and-sangamo-therapeutics-announce-phase-3-trial-investigational-gene
   Google Scholar
• Chowdary P, Shapiro S, Makris M, et al. Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B. N Engl J Med. 2022;387(3):237–247. doi: 10.1056/NEJMoa2119913
   PubMed Web of Science ®Google Scholar
• Polderdijk SG, Adams TE, Ivanciu L, et al. Design and characterization of an APC-specific serpin for the treatment of hemophilia. Blood. 2017;129(1):105–113. doi: 10.1182/blood-2016-05-718635
   PubMed Web of Science ®Google Scholar
• Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706–718. doi: 10.1056/NEJMoa2211644
   PubMed Web of Science ®Google Scholar
• von Drygalski A, Gomez E, Giermasz A, et al. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy. Blood Adv. 2023;7(19):5671–5679. doi: 10.1182/bloodadvances.2022008886
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Kaczmarek R, von Drygalski A, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia a. N Engl J Med. 2023;388(8):694–705. doi: 10.1056/NEJMoa2211075
   PubMed Web of Science ®Google Scholar
• Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013–1025. doi: 10.1056/NEJMoa2113708
   PubMed Web of Science ®Google Scholar
• George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215–2227. doi: 10.1056/NEJMoa1708538
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss U, Tuddenham E, et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing “empty viral particles” on safety and efficacy of gene transfer. Blood. 2018;132(Supplement 1):491–491. doi: 10.1182/blood-2018-99-118334
   Google Scholar
• Miesbach W, Meijer K, Coppens M, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 2018;131(9):1022–1031. doi: 10.1182/blood-2017-09-804419
   PubMed Web of Science ®Google Scholar
• Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361(17):1671–1675. doi: 10.1056/NEJMoa0904377
   PubMed Web of Science ®Google Scholar
• Spronck EA, Liu YP, Lubelski J, et al. Enhanced factor IX activity following administration of AAV5-R338L “Padua” factor IX versus AAV5 WT human factor IX in NHPs. Mol Ther Methods Clin Dev. 2019;15:221–231. doi: 10.1016/j.omtm.2019.09.005
   PubMed Web of Science ®Google Scholar
• von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019;3(21):3241–3247. doi: 10.1182/bloodadvances.2019000811
   PubMed Web of Science ®Google Scholar
• VandenDriessche T, Chuah MK. Hyperactive factor IX Padua: a game-changer for hemophilia gene therapy. Mol Ther. 2018;26(1):14–16. doi: 10.1016/j.ymthe.2017.12.007
   PubMed Web of Science ®Google Scholar
• Samelson-Jones BJ, Arruda VR. Protein-engineered coagulation factors for hemophilia gene therapy. Mol Ther Methods Clin Dev. 2019;12:184–201. doi: 10.1016/j.omtm.2018.12.007
   PubMed Web of Science ®Google Scholar
• Majowicz A, Nijmeijer B, Lampen MH, et al. Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs. Mol Ther Methods Clin Dev. 2019;14:27–36. doi: 10.1016/j.omtm.2019.05.009
   PubMed Web of Science ®Google Scholar
• Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342–347. doi: 10.1038/nm1358
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994–2004. doi: 10.1056/NEJMoa1407309
   PubMed Web of Science ®Google Scholar
• Miesbach W, Recht M, Key N, et al. Durability of factor IX activity and bleeding rate in people with severe or moderately severe hemophilia B after 5 years of follow-up in the Phase 1/2 study of AMT-060, and after 3 years of follow-up in the Phase 2b and 2 years of follow-up in the Phase 3 studies of etranacogene dezaparvovec (AMT-061). Blood. 2022;140(Supplement 1):4913–4914. doi: 10.1182/blood-2022-166810
   Google Scholar
• Wang L, Calcedo R, Bell P, et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther. 2011;22(11):1389–1401. doi: 10.1089/hum.2011.031
   PubMed Web of Science ®Google Scholar
• Jiang H, Couto LB, Patarroyo-White S, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood. 2006;108(10):3321–3328. doi: 10.1182/blood-2006-04-017913
   PubMed Web of Science ®Google Scholar
• Scallan CD, Jiang H, Liu T, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood. 2006;107(5):1810–1817. doi: 10.1182/blood-2005-08-3229
   PubMed Web of Science ®Google Scholar
• Meliani A, Leborgne C, Triffault S, et al. Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum Gene Ther Methods. 2015;26(2):45–53. doi: 10.1089/hgtb.2015.037
   PubMed Web of Science ®Google Scholar
• Schmidt M, Foster GR, Coppens M, et al. Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B. Blood Adv. 2023;7(17):4966–4969. doi: 10.1182/bloodadvances.2023009876
   PubMed Web of Science ®Google Scholar
• Castaman G. Gene transfer in hemophilia B: a big step forward. Bleeding, Thrombosis, And Vascular Biology. 2023;2(2). doi: 10.4081/btvb.2023.70
   Google Scholar
• Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia a. N Engl J Med. 2017;377(26):2519–2530. doi: 10.1056/NEJMoa1708483
   PubMed Web of Science ®Google Scholar
• Pipe S, Leebeek F, Recht M, et al. Adults with severe or moderately severe hemophilia B receiving etranacogene dezaparvovec in the HOPE-B Phase 3 clinical trial continue to experience a stable increase in mean factor IX activity levels and durable hemostatic protection after 24 months’ follow-up. Blood. 2022;140(Supplement 1):4910–4912. doi: 10.1182/blood-2022-166135
   Google Scholar
• Klamroth R, Hayes G, Andreeva T, et al. Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia a. Hum Gene Ther. 2022;33(7–8):432–441. doi: 10.1089/hum.2021.287
   PubMed Web of Science ®Google Scholar
• Leebeek FWG, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. 2021;138(11):923–931. doi: 10.1182/blood.2019003777
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Laffan M, Rangarajan S, et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia a. Haemophilia. 2021;27(6):947–956. doi: 10.1111/hae.14391
   PubMed Web of Science ®Google Scholar
• Visweshwar N, Harrington TJ, Leavitt AD, et al. Updated results of the Alta study, a Phase 1/2 study of giroctocogene fitelparvovec (PF-07055480/SB-525) gene therapy in adults with severe hemophilia a. Blood. 2021;138(Supplement 1):564. doi: 10.1182/blood-2021-148651
   Google Scholar
• Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol. 2001;21(5):731–738. doi: 10.1161/01.ATV.21.5.731
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. Pfizer/Sangamo therapeutics report severe adverse event (SAE) from phase 3 AFFINE haemophilia a gene therapy study 2022 [23 Jan 2023]. Available from: https://wfh.org/article/pfizer-sangamo-therapeutics-report-severe-adverse-event-sae-from-phase-3-affine-haemophilia-a-gene-therapy-study/
   Google Scholar
• Franchini M, Mannucci PM. Non-factor replacement therapy for haemophilia: a current update. Blood Transfus. 2018;16(5):457–461. doi: 10.2450/2018.0272-17
   PubMed Web of Science ®Google Scholar
• National Hemophilia Foundation. Sanofi revises fitusiran dosing regimen to mitigate risk of vascular thrombosis 2021 [06 Jun 2023]. Available from: https://www.hemophilia.org/news/sanofi-revises-fitusiran-dosing-regimen-to-mitigate-risk-of-vascular-thrombosis
   Google Scholar
• Tiede A. Thromboembolic risks of non-factor replacement therapies in hemophilia. Hamostaseologie. 2017;37(4):307–310. doi: 10.5482/20170004
   PubMed Web of Science ®Google Scholar
• Foley JH, Shehu E, Riddell A, et al. Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies. Blood Adv. 2023;7(3):458–467. doi: 10.1182/bloodadvances.2022007435
   PubMed Web of Science ®Google Scholar
• Miesbach W, Meijer K, Coppens M, et al. Five year data confirms stable FIX expression and sustained reductions in bleeding and factor IX use following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B. Res Pract Thromb Haemost. 2021;5(Suppl 2): 90.
   Google Scholar
• Croteau S, Eyster M, Tran H, et al. Long-term durable FVIII expression with improvements in bleeding rates following AAV-mediated FVIII gene transfer for hemophilia A: multiyear follow-up on the Phase I/II trial of SPK-8011. Blood. 2022;140(Supplement 1):1899–1901. doi: 10.1182/blood-2022-158903
   Google Scholar
• Pipe SW. Lifelong gene therapy in dogs with hemophilia a. Blood. 2022;140(25):2650–2652. doi: 10.1182/blood.2022016359
   PubMed Web of Science ®Google Scholar
• Pipe SW, Sheehan JP, Coppens M, et al. First-in-human dose-finding study of AAVhu37 vector-based gene therapy: BAY 2599023 has stable and sustained expression of FVIII over 2 years. Blood. 2021;138(Supplement 1):3971–3971. doi: 10.1182/blood-2021-148661
   Google Scholar
• Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23–36. doi: 10.1182/blood-2013-01-306647
   PubMed Web of Science ®Google Scholar
• Poothong J, Pottekat A, Siirin M, et al. Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum. Blood. 2020;135(21):1899–1911. doi: 10.1182/blood.2019002867
   PubMed Web of Science ®Google Scholar
• Astermark J, Lucas S, Chen L, et al. Analysis of elevated alanine transaminase in HOPE-B, a Phase 3 recombinant adeno-associated viral 5 gene therapy trial in people with haemophilia B (PO040). Haemophilia. 2023;29(S1):43.
   Google Scholar
• Miesbach W, O’Mahony B, Key NS, et al. How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia. 2019;25(4):545–557. doi: 10.1111/hae.13769
   PubMed Web of Science ®Google Scholar
• BioMarin. BioMarin Announces durable Hemostatic efficacy maintained over 6 years in Ongoing Phase 1/2 study of valoctocogene roxaparvovec, investigational gene therapy for hemophilia a 2022. Available from: https://investors.biomarin.com/2022-05-31-BioMarin-Announces-Durable-Hemostatic-Efficacy-Maintained-Over-6-years-in-Ongoing-Phase-1-2-Study-of-Valoctocogene-Roxaparvovec,-Investigational-Gene-Therapy-for-Hemophilia-A
   Google Scholar
• United States Securities and Exchange Commission . BioMarin Pharamceuticals Inc Form. 2022;8–K.
   Google Scholar
• Miesbach W, Foster GR, Peyvandi F. Liver-related aspects of gene therapy for haemophilia: call to action for collaboration between haematologists and hepatologists. J Hepatol. 2023;78(3):467–470. doi: 10.1016/j.jhep.2022.11.014
   PubMed Web of Science ®Google Scholar
• Miesbach W, Foster G, Peyvandi F. Liver-related aspects of gene therapy for haemophilia: need for collaborations with hepatologists. J Thromb Haemost. 2023;21(2):200–203. doi: 10.1016/j.jtha.2022.11.026
   PubMed Web of Science ®Google Scholar
• Konkle BA, Coffin D, Pierce GF, et al. World Federation of hemophilia gene therapy registry. Haemophilia. 2020;26(4):563–564. doi: 10.1111/hae.14015
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Long term follow-up after administration of human gene therapy products 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products
   Google Scholar
• World Federation of Hemophilia Gene Therapy Registry 2022. Available from: https://elearning.wfh.org/resource/the-world-federation-of-hemophilia-gene-therapy-registry-informational-webinar/
   Google Scholar
• Limjoco J, Thornburg CD. Gene therapy for hemophilia A: a mixed methods study of patient preferences and shared decision-making. Patient Prefer Adherence. 2023;17:1093–1105. doi: 10.2147/PPA.S406894
   PubMed Web of Science ®Google Scholar
• Fletcher S, Jenner K, Pembroke L, et al. The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the exigency study. Orphanet J Rare Dis. 2022;17(1):155. doi: 10.1186/s13023-022-02256-2
   PubMed Web of Science ®Google Scholar
• Witkop M, Morgan G, O’Hara J, et al. Patient preferences and priorities for haemophilia gene therapy in the US: a discrete choice experiment. Haemophilia. 2021;27(5):769–782. doi: 10.1111/hae.14383
   PubMed Web of Science ®Google Scholar
• van Overbeeke E, Michelsen S, Hauber B, et al. Patient perspectives regarding gene therapy in haemophilia: interviews from the PAVING study. Haemophilia. 2021;27(1):129–136. doi: 10.1111/hae.14190
   PubMed Web of Science ®Google Scholar
• Fletcher S, Jenner K, Holland M, et al. An exploration of why men with severe haemophilia might not want gene therapy: the exigency study. Haemophilia. 2021;27(5):760–768. doi: 10.1111/hae.14378
   PubMed Web of Science ®Google Scholar
• Miesbach W, Chowdary P, Coppens M, et al. Delivery of AAV-based gene therapy through haemophilia centres-A need for re-evaluation of infrastructure and comprehensive care: a joint publication of EAHAD and EHC. Haemophilia. 2021;27(6):967–973. doi: 10.1111/hae.14420
   PubMed Web of Science ®Google Scholar
• EAHAD – EHC Statement on Gene Therapies Hub-and-Spoke Model [Apr 2023]. Available from: https://www.eahad.org/eahad-ehc-statement-on-promoting-hub-and-spoke-model-using-gene-therapies/
   Google Scholar
• European Medicines Agency. Summary of opinion: initial authorisation HEMGENIX 2022. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hemgenix_en.pdf
   Google Scholar
• Miesbach W, Recht M, Key NS, et al. Durability of response after long-term follow-up in the Phase 1/2 study of AMT-060, and Phase 2b and 3 studies of etranacogene dezaparvovec in haemophilia B. Haemophilia. 2023;29(S1):24–202.
   Google Scholar
• Institute for Clinical and Economic Review. Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: final Policy Recommendations [Accessed Jan 2023]. Available from: https://icer.org/wp-content/uploads/2022/12/ICER-Hemophilia-Policy-Recommendations-122222.pdf
   Google Scholar